HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IdeaSphere markets Weil

This article was originally published in The Tan Sheet

Executive Summary

IdeaSphere will "assume exclusive, worldwide licensing rights" to Weil Nutritional Supplements, the New York-based firm announced Jan. 17. The product line, which was launched in March by author Andrew Weil, MD, currently is sold through Weil's website and in specialty health stores such as Whole Foods, GNC and Vitamin Shoppe. IdeaSphere will take over retail and direct marketing of the supplement line including online sales, the company states. IdeaSphere purchased Twinlab in 2003 and most recently completed the acquisition of Metabolife's non-ephedra brands including Metabolife Ultra in November (1"The Tan Sheet" Sept. 1, 2003, p. 3 and 2"The Tan Sheet" Nov. 14, 2005, In Brief)...

You may also be interested in...



Twinlab Finds Potential Buyer In IdeaSphere: End Of Blechman Era?

The proposed acquisition of Twinlab by nutritional products seller IdeaSphere would mark the end of the Blechman family ownership of the company, in place since the company's founding 35 years ago

Glenmark’s Ryaltris Set To Hit Canadian Market

Health Canada approves Ryaltris for allergic rhinitis, opening up yet another major market for Glenmark’s branded specialty medicine. Bausch Health will sell the drug in Canada.

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS126057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel